Participant flow

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) · Source last updated 2026-02-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.

   id

   FG000

   title

   Pembrolizumab + Axitinib

2. description

   Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.

   id

   FG001

   title

   Sunitinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         59

      2. group Id

         FG001

         num Subjects

         95

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         9

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         368

      2. group Id

         FG001

         num Subjects

         325

      type

      Ongoing in study

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         432

      2. group Id

         FG001

         num Subjects

         429

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         429

      2. group Id

         FG001

         num Subjects

         425

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         432

      2. group Id

         FG001

         num Subjects

         429

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

These interim results are based on a database cutoff date of 24-Aug-2018, at which time 693 participants were ongoing in the study.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice